ClinicalTrials.gg
CompletedNCT01401166PrefHERUpdated Mar 6, 2017Results posted

Participant Preference of Subcutaneous (SC) Versus Intravenous (IV) Herceptin (Trastuzumab) in Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer

A Phase 2 interventional study of Herceptin and Herceptin in Breast Neoplasms, sponsored by Hoffmann-La Roche. Completed at 75 sites in 12 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-06.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Health services research

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
488
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 374 studies testing trastuzumab in Breast Neoplasms — 57 open to participants now, 86 under way, 5 of them phase 3. Trastuzumab · Breast Neoplasms.

Enrollment
39th of 366
488 · median 61
Started
2011
with 18 others
Phase 2
239 of 374
44 open now
Registered
175th of 374
by date
Lead sponsor
31 of 374
Hoffmann-La Roche

Among the 374 studies testing trastuzumab in Breast Neoplasms, this one is the 39th largest by enrollment of the 366 interventional ones that give a count, is one of 19 that started in 2011, is one of 239 in phase 2, and was the 175th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

57 of the 374 studies testing trastuzumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About trastuzumab

Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 374 studies testing trastuzumab in Breast Neoplasms, or all of them as a file.
02

Study summary

This randomized, open-label, crossover study will evaluate participants' preference and healthcare professional (HCP) satisfaction with SC versus IV Herceptin administration in HER2-positive early breast cancer. Participants will be randomized to receive either SC Herceptin or IV Herceptin every 3 weeks for Cycles 1 to 4, followed by crossover to the other treatment administration for Cycles 5 to 8. For up to 10 additional cycles (for a total of 18 cycles), participants will receive IV or SC Herceptin every 3 weeks.

03

Conditions studied

  • Breast Neoplasms

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed -positive primary breast cancer
  • No evidence of residual, locally recurrent, or disease after completion of surgery and chemotherapy ( or adjuvant)
  • Completed neo-adjuvant chemotherapy prior to entry, if received
  • At least 8 remaining cycles out of the total 18 planned 3-week cycles, if received IV Herceptin
  • (ECOG) performance status 0 or 1

Exclusion criteria

Exclusion Criteria:

  • History of other , except for ductal carcinoma in situ of the breast, curatively treated carcinoma in situ of the cervix, basal cell carcinoma, or other curatively treated malignancies of which the participant has been disease-free for at least 5 years
  • Inadequate bone marrow function
  • Impaired liver function
  • Inadequate renal function
  • Serious cardiovascular disease
  • or or C infection
  • Prior maximum cumulative dose of doxorubicin greater than (>) 360 milligrams per meter-squared (mg/m\^2) or epirubicin >720 mg/m\^2 or equivalent
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
488 participants (actual)

Study arms

  • Experimental
    Cohort 1: SC (SID) then IV Herceptin

    Participants will receive Herceptin on Day 1 of each 3-week cycle for 18 cycles. During Cycles 1 to 4 of the crossover period, SC Herceptin will be administered via single-use injection device (SID), and during Cycles 5 to 8, IV Herceptin will be given. In the continuation period, participants will receive IV Herceptin for up to 10 remaining cycles. Administration will be performed by HCP. Those with at least 2 treatment cycles remaining of the 18-cycle treatment course after the crossover period will be offered the opportunity to self-administer SC Herceptin via SID under the direction of a trained HCP.

    Drug: Herceptin · Device: Single-Use Injection Device

  • Experimental
    Cohort 1: IV then SC (SID) Herceptin

    Participants will receive Herceptin on Day 1 of each 3-week cycle for 18 cycles. During Cycles 1 to 4 of the crossover period, IV Herceptin will be given, and during Cycles 5 to 8, SC Herceptin will be administered via SID. In the continuation period, participants will receive IV Herceptin for up to 10 remaining cycles. Administration will be performed by HCP. Those with at least 2 treatment cycles remaining of the 18-cycle treatment course after the crossover period will be offered the opportunity to self-administer SC Herceptin via SID under the direction of a trained HCP.

    Drug: Herceptin · Device: Single-Use Injection Device

  • Experimental
    Cohort 2: SC (Vial) then IV Herceptin

    Participants will receive Herceptin on Day 1 of each 3-week cycle for 18 cycles. During Cycles 1 to 4 of the crossover period, SC Herceptin will be administered via handheld syringe using the vial formulation, and during Cycles 5 to 8, IV Herceptin will be given. In the continuation period, participants will receive SC Herceptin via handheld syringe using the vial formulation for up to 10 remaining cycles. Administration will be performed by HCP throughout the study.

    Drug: Herceptin

  • Experimental
    Cohort 2: IV then SC (Vial) Herceptin

    Participants will receive Herceptin on Day 1 of each 3-week cycle for 18 cycles. During Cycles 1 to 4 of the crossover period, IV Herceptin will be given, and during Cycles 5 to 8, SC Herceptin will be administered via handheld syringe using the vial formulation. In the continuation period, participants will receive SC Herceptin via handheld syringe using the vial formulation for up to 10 remaining cycles. Administration will be performed by HCP throughout the study.

    Drug: Herceptin

Interventions

  • Herceptin will be given on Day 1 of each 3-week cycle for a total of 18 cycles. If study treatment for Cycle 1 is IV Herceptin, the initial dose will be a loading dose of 8 milligrams per kilogram (mg/kg) for de novo participants who start Herceptin treatment in the study. For all other cycles where IV Herceptin is given and for non-de novo participants, the dose will be 6 mg/kg. The SC dose will be 600 milligrams (mg) for both the SID and vial formulations for all cycles where SC Herceptin is given.

    Also known as: Trastuzumab

  • Herceptin will be given on Day 1 of each 3-week cycle for a total of 18 cycles. If study treatment for Cycle 1 is IV Herceptin, the initial dose will be a loading dose of 8 mg/kg for de novo participants who start Herceptin treatment in the study. For all other cycles where IV Herceptin is given and for non-de novo participants, the dose will be 6 mg/kg. The SC dose will be 600 mg for both the SID and vial formulations for all cycles where SC Herceptin is given.

    Also known as: Trastuzumab

  • DeviceSingle-Use Injection Device

    The SID will be used, containing Herceptin 600 mg per 5 milliliters (mL).

  • DeviceSingle-Use Injection Device

    The SID will be used, containing Herceptin 600 mg per 5 mL.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants by Preferred Method of Drug Administration

    The preferred method of drug administration (IV or SC Herceptin) was assessed in trial-specific telephone interviews with each study participant. Participants were asked, "All things considered, which method of administration did you prefer?" at the end of the crossover period (Week 24). The percentage of participants who preferred each method of drug administration was reported.

    Time frame: Week 24

Secondary outcomes

  1. Percentage of HCPs by Most Satisfied Method of Drug Administration

    The method of drug administration with which HCPs were most satisfied (IV or SC Herceptin) was assessed via questionnaire with each HCP using the question, "All things considered, with which method of administration were you most satisfied?" at the end of the crossover period (Week 24). The percentage of HCPs who were most satisfied with each method of drug administration was reported.

    Time frame: Week 24

  2. Percentage of HCPs by Time Required to Perform Each Method of Drug Administration

    The time required to perform each method of drug administration was assessed via questionnaire with each HCP by asking to rate the amount of time it took to administer each method of drug administration (IV or SC Herceptin) at the end of the crossover period (Week 24). Time was rated in the following time block categories: less than (\<) 5 minutes, 6 to 10 minutes, 11 to 15 minutes, 16 to 20 minutes, and greater than (\>) 20 minutes. Responses of "Not Sure" and "Unknown" were also allowed. The percentage of HCPs who rated the amount of time in each of the categories was reported.

    Time frame: Week 24

  3. Percentage of Participants With an Event-Free Survival (EFS) Event

    EFS events included local, regional, or distant recurrence of the original breast cancer, occurrence of contralateral breast cancer, or death due to any cause. The percentage of participants who had an EFS event at any time on study was reported.

    Time frame: From Baseline until time of event; assessed every 6 months (median follow-up of 3 years)

  4. Duration of EFS According to Kaplan-Meier Estimate

    EFS was defined as the time from randomization to a local, regional, or distant recurrence of the original breast cancer, occurrence of contralateral breast cancer, or death due to any cause. The median duration of EFS and corresponding 95 percent (%) CI according to Kaplan-Meier estimates were planned to be reported and expressed in months.

    Time frame: From Baseline until time of event; assessed every 6 months (median follow-up of 3 years)

  5. 3-Year EFS Rate

    EFS events included local, regional, or distant recurrence of the original breast cancer, occurrence of contralateral breast cancer, or death due to any cause. The proportion of participants without an EFS event (i.e., the EFS rate) and corresponding 95% CI at 3 years after randomization was reported.

    Time frame: Year 3

  6. Percentage of Participants With Responses of "Agree" or "Strongly Agree" on the SC SID Satisfaction Questionnaire

    Participants who performed self-administration of SC Herceptin via SID were given an evaluation questionnaire during the continuation period (Weeks 25 to 52) after their first self-administration. Participants responded to 5 statements about their comfort with self-injection, the convenience of the SID, their self-confidence using the SID, their satisfaction with the SID, and whether they would consider using the SID again in the future. Each statement used a 5-item rating scale with responses from "Strongly Disagree" to "Strongly Agree". The percentage of participants with a positive response (either "Agree" or "Strongly Agree") to each questionnaire statement was reported.

    Time frame: Immediately following first self-administration of SC Herceptin via SID (once during Weeks 25 to 52)

  7. Percentage of Participants With Anti-Trastuzumab or Anti-Recombinant Human Hyaluronidase (rHuPH20) Antibodies

    Participants in Cohort 1 provided blood samples for immunogenicity testing to assess for anti-drug antibodies (ADAs) to trastuzumab or rHuPH20, a component of the SC Herceptin formulation. The percentage of participants who were trastuzumab ADA-positive and the percentage of participants who were rHuPH20 ADA-positive were each reported.

    Time frame: Baseline, pre-dose (0 hours) during Cycle 5 (cycle length of 3 weeks)

07

Results

Posted Jun 8, 2015

Participant flow

Crossover Treatment 1 (Cycles 1 to 4)
Participant flow — Crossover Treatment 1 (Cycles 1 to 4)
MilestoneCohort 1: SC (SID) Then IV HerceptinCohort 1: IV Then SC (SID) HerceptinCohort 2: SC (Vial) Then IV HerceptinCohort 2: IV Then SC (Vial) Herceptin
Started122122121118
Completed119120119116
Not completed3222
Crossover Treatment 2 (Cycles 5 to 8)
Participant flow — Crossover Treatment 2 (Cycles 5 to 8)
MilestoneCohort 1: SC (SID) Then IV HerceptinCohort 1: IV Then SC (SID) HerceptinCohort 2: SC (Vial) Then IV HerceptinCohort 2: IV Then SC (Vial) Herceptin
Started119120119116
Completed113116107105
Not completed641211
Continuation Treatment (Cycles 9 to 18)
Participant flow — Continuation Treatment (Cycles 9 to 18)
MilestoneCohort 1: SC (SID) Then IV HerceptinCohort 1: IV Then SC (SID) HerceptinCohort 2: SC (Vial) Then IV HerceptinCohort 2: IV Then SC (Vial) Herceptin
Started113116107105
Completed109109105102
Not completed4723
Safety Follow-Up Period
Participant flow — Safety Follow-Up Period
MilestoneCohort 1: SC (SID) Then IV HerceptinCohort 1: IV Then SC (SID) HerceptinCohort 2: SC (Vial) Then IV HerceptinCohort 2: IV Then SC (Vial) Herceptin
Started124124121119
Completed99106104100
Not completed25181719

Outcome measures

PrimaryPercentage of Participants by Preferred Method of Drug Administration

The preferred method of drug administration (IV or SC Herceptin) was assessed in trial-specific telephone interviews with each study participant. Participants were asked, "All things considered, which method of administration did you prefer?" at the end of the crossover period (Week 24). The percentage of participants who preferred each method of drug administration was reported.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants by Preferred Method of Drug Administration
percentage of participantsCohort 1: SC (SID) Then IV HerceptinCohort 1: IV Then SC (SID) HerceptinCohort 2: SC (Vial) Then IV HerceptinCohort 2: IV Then SC (Vial) Herceptin
SC Herceptin95.787.483.988.5
IV Herceptin4.39.213.611.5
No Preference0.03.42.50.0
Statistical analysis
  • Cohort 1: SC (SID) Then IV Herceptin · Estimated proportion: 0.957 · 95% CI 0.903 to 0.986The estimated proportion of participants who preferred SC Herceptin and the corresponding exact binomial confidence interval (CI) were determined.
  • Cohort 1: SC (SID) Then IV Herceptin · Estimated proportion: 0.964 · 95% CI 0.908 to 0.986The estimated proportion of participants who preferred SC Herceptin and the corresponding CI were determined using logistic regression with factors of previous Herceptin status and treatment.
  • Cohort 1: IV Then SC (SID) Herceptin · Estimated proportion: 0.874 · 95% CI 0.801 to 0.928The estimated proportion of participants who preferred SC Herceptin and the corresponding exact binomial CI were determined.
  • Cohort 1: IV Then SC (SID) Herceptin · Estimated proportion: 0.892 · 95% CI 0.804 to 0.943The estimated proportion of participants who preferred SC Herceptin and the corresponding CI were determined using logistic regression with factors of previous Herceptin status and treatment.
  • Cohort 2: SC (Vial) Then IV Herceptin · Estimated proportion: 0.839 · 95% CI 0.760 to 0.900The estimated proportion of participants who preferred SC Herceptin and the corresponding exact binomial CI were determined.
  • Cohort 2: SC (Vial) Then IV Herceptin · Estimated proportion: 0.874 · 95% CI 0.776 to 0.933The estimated proportion of participants who preferred SC Herceptin and the corresponding CI were determined using logistic regression with factors of previous Herceptin status and treatment.
  • Cohort 2: IV Then SC (Vial) Herceptin · Estimated proportion: 0.885 · 95% CI 0.811 to 0.937The estimated proportion of participants who preferred SC Herceptin and the corresponding exact binomial CI were determined.
  • Cohort 2: IV Then SC (Vial) Herceptin · Estimated proportion: 0.911 · 95% CI 0.827 to 0.956The estimated proportion of participants who preferred SC Herceptin and the corresponding CI were determined using logistic regression with factors of previous Herceptin status and treatment.
SecondaryPercentage of HCPs by Most Satisfied Method of Drug Administration

The method of drug administration with which HCPs were most satisfied (IV or SC Herceptin) was assessed via questionnaire with each HCP using the question, "All things considered, with which method of administration were you most satisfied?" at the end of the crossover period (Week 24). The percentage of HCPs who were most satisfied with each method of drug administration was reported.

Time frame:
Week 24
Reported as:
Number · percentage of HCPs
Percentage of HCPs by Most Satisfied Method of Drug Administration
percentage of HCPsAll HCPs: SC and IV Herceptin
SC Herceptin77.0
IV Herceptin3.0
No Preference20.0
SecondaryPercentage of HCPs by Time Required to Perform Each Method of Drug Administration

The time required to perform each method of drug administration was assessed via questionnaire with each HCP by asking to rate the amount of time it took to administer each method of drug administration (IV or SC Herceptin) at the end of the crossover period (Week 24). Time was rated in the following time block categories: less than (\<) 5 minutes, 6 to 10 minutes, 11 to 15 minutes, 16 to 20 minutes, and greater than (\>) 20 minutes. Responses of "Not Sure" and "Unknown" were also allowed. The percentage of HCPs who rated the amount of time in each of the categories was reported.

Time frame:
Week 24
Reported as:
Number · percentage of HCPs
Percentage of HCPs by Time Required to Perform Each Method of Drug Administration
percentage of HCPsAll HCPs: SC and IV Herceptin
SC Herceptin, <5 minutes44.3
SC Herceptin, 6 to 10 minutes46.4
SC Herceptin, 11 to 15 minutes3.4
SC Herceptin, 16 to 20 minutes0.4
SC Herceptin, >20 minutes0.4
SC Herceptin, Not Sure0.0
SC Herceptin, Unknown5.1
IV Herceptin, <5 minutes11.1
IV Herceptin, 6 to 10 minutes9.8
IV Herceptin, 11 to 15 minutes3.8
IV Herceptin, 16 to 20 minutes44.3
IV Herceptin, >20 minutes22.1
IV Herceptin, Not Sure5.1
IV Herceptin, Unknown3.8
SecondaryPercentage of Participants With an Event-Free Survival (EFS) Event

EFS events included local, regional, or distant recurrence of the original breast cancer, occurrence of contralateral breast cancer, or death due to any cause. The percentage of participants who had an EFS event at any time on study was reported.

Time frame:
From Baseline until time of event; assessed every 6 months (median follow-up of 3 years)
Reported as:
Number · percentage of participants
Percentage of Participants With an Event-Free Survival (EFS) Event
percentage of participantsCohort 1: SC (SID) Then IV HerceptinCohort 1: IV Then SC (SID) HerceptinCohort 2: SC (Vial) Then IV HerceptinCohort 2: IV Then SC (Vial) Herceptin
Percentage of Participants With an Event-Free Survival (EFS) Event13.76.711.97.1
SecondaryDuration of EFS According to Kaplan-Meier Estimate

EFS was defined as the time from randomization to a local, regional, or distant recurrence of the original breast cancer, occurrence of contralateral breast cancer, or death due to any cause. The median duration of EFS and corresponding 95 percent (%) CI according to Kaplan-Meier estimates were planned to be reported and expressed in months.

Time frame:
From Baseline until time of event; assessed every 6 months (median follow-up of 3 years)
Reported as:
Median · months
Duration of EFS According to Kaplan-Meier Estimate
monthsCohort 1: SC (SID) Then IV HerceptinCohort 1: IV Then SC (SID) HerceptinCohort 2: SC (Vial) Then IV HerceptinCohort 2: IV Then SC (Vial) Herceptin
Duration of EFS According to Kaplan-Meier EstimateNA (NA to NA)NA (42.0 to NA)NA (NA to NA)NA (NA to NA)
Secondary3-Year EFS Rate

EFS events included local, regional, or distant recurrence of the original breast cancer, occurrence of contralateral breast cancer, or death due to any cause. The proportion of participants without an EFS event (i.e., the EFS rate) and corresponding 95% CI at 3 years after randomization was reported.

Time frame:
Year 3
Reported as:
Number · proportion of participants
3-Year EFS Rate
proportion of participantsCohort 1: SC (SID) Then IV HerceptinCohort 1: IV Then SC (SID) HerceptinCohort 2: SC (Vial) Then IV HerceptinCohort 2: IV Then SC (Vial) Herceptin
3-Year EFS Rate0.849 (0.763 to 0.906)0.948 (0.887 to 0.976)0.886 (0.811 to 0.932)0.937 (0.873 to 0.970)
SecondaryPercentage of Participants With Responses of "Agree" or "Strongly Agree" on the SC SID Satisfaction Questionnaire

Participants who performed self-administration of SC Herceptin via SID were given an evaluation questionnaire during the continuation period (Weeks 25 to 52) after their first self-administration. Participants responded to 5 statements about their comfort with self-injection, the convenience of the SID, their self-confidence using the SID, their satisfaction with the SID, and whether they would consider using the SID again in the future. Each statement used a 5-item rating scale with responses from "Strongly Disagree" to "Strongly Agree". The percentage of participants with a positive response (either "Agree" or "Strongly Agree") to each questionnaire statement was reported.

Time frame:
Immediately following first self-administration of SC Herceptin via SID (once during Weeks 25 to 52)
Reported as:
Number · percentage of participants
Percentage of Participants With Responses of "Agree" or "Strongly Agree" on the SC SID Satisfaction Questionnaire
percentage of participantsCohort 1: SC (SID) Then IV HerceptinCohort 1: IV Then SC (SID) Herceptin
Comfortable94.786.7
Convenient100100
Confident100100
Satisfied10093.3
Would Use Again10093.3
SecondaryPercentage of Participants With Anti-Trastuzumab or Anti-Recombinant Human Hyaluronidase (rHuPH20) Antibodies

Participants in Cohort 1 provided blood samples for immunogenicity testing to assess for anti-drug antibodies (ADAs) to trastuzumab or rHuPH20, a component of the SC Herceptin formulation. The percentage of participants who were trastuzumab ADA-positive and the percentage of participants who were rHuPH20 ADA-positive were each reported.

Time frame:
Baseline, pre-dose (0 hours) during Cycle 5 (cycle length of 3 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Anti-Trastuzumab or Anti-Recombinant Human Hyaluronidase (rHuPH20) Antibodies
percentage of participantsCohort 1: SC (SID) Then IV HerceptinCohort 1: IV Then SC (SID) Herceptin
Trastuzumab ADA-Positive, Baseline (n=120,121)2.54.1
Trastuzumab ADA-Positive, Cycle 5 (n=114,119)03.4
rHuPH20 ADA-Positive, Baseline (n=120,121)5.87.4
rHuPH20 ADA-Positive, Cycle 5 (n=115,119)2.67.6

Adverse events

Collected over During treatment from Cycles 1 to 8 (crossover period) and Cycles 9 to 18 (continuation period); cycle length of 3 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: SC (SID) Herceptin (Crossover)—4/242 (1.7%)81/242 (33.5%)
Cohort 1: IV Herceptin (Crossover)—2/241 (0.8%)55/241 (22.8%)
Cohort 1: IV Herceptin (Continuation)—6/226 (2.7%)46/226 (20.4%)
Cohort 1: SC (SID) Herceptin (Continuation)—1/43 (2.3%)7/43 (16.3%)
Cohort 1 Overall: SC (SID) and IV Herceptin—12/244 (4.9%)130/244 (53.3%)
Cohort 2: SC (Vial) Herceptin (Crossover)—0/237 (0%)107/237 (45.1%)
Cohort 2: IV Herceptin (Crossover)—2/237 (0.8%)76/237 (32.1%)
Cohort 2: IV Herceptin (Continuation)—0/10 (0%)6/10 (60%)
Cohort 2: SC (Vial) Herceptin (Continuation)—5/208 (2.4%)61/208 (29.3%)
Cohort 2 Overall: SC (Vial) and IV Herceptin—7/239 (2.9%)154/239 (64.4%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventCohort 1: SC (SID) Herceptin (Crossover)Cohort 1: IV Herceptin (Crossover)Cohort 1: IV Herceptin (Continuation)Cohort 1: SC (SID) Herceptin (Continuation)Cohort 1 Overall: SC (SID) and IV HerceptinCohort 2: SC (Vial) Herceptin (Crossover)Cohort 2: IV Herceptin (Crossover)Cohort 2: IV Herceptin (Continuation)Cohort 2: SC (Vial) Herceptin (Continuation)Cohort 2 Overall: SC (Vial) and IV Herceptin
Cerebral haemangiomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2420/2410/2261/431/2440/2370/2370/100/2080/239
Wound infectionInfections and infestations0/2420/2410/2260/430/2440/2371/2370/101/2082/239
Breast reconstructionSurgical and medical procedures0/2420/2410/2260/430/2440/2370/2370/101/2081/239
Knee arthroplastySurgical and medical procedures0/2420/2410/2260/430/2440/2370/2370/101/2081/239
MammoplastySurgical and medical procedures0/2420/2410/2260/430/2440/2370/2370/101/2081/239
Left ventricular dysfunctionCardiac disorders0/2420/2410/2260/430/2440/2370/2370/101/2081/239
Breast abscessInfections and infestations0/2420/2411/2260/431/2440/2370/2370/100/2080/239
Postoperative wound infectionInfections and infestations0/2420/2411/2260/431/2440/2370/2370/100/2080/239
PyelonephritisInfections and infestations0/2420/2411/2260/431/2440/2370/2370/100/2080/239
Adverse drug reactionGeneral disorders0/2420/2411/2260/431/2440/2370/2370/100/2080/239
Most frequent other events
Showing 10 of 26
Most frequent other events
EventCohort 1: SC (SID) Herceptin (Crossover)Cohort 1: IV Herceptin (Crossover)Cohort 1: IV Herceptin (Continuation)Cohort 1: SC (SID) Herceptin (Continuation)Cohort 1 Overall: SC (SID) and IV HerceptinCohort 2: SC (Vial) Herceptin (Crossover)Cohort 2: IV Herceptin (Crossover)Cohort 2: IV Herceptin (Continuation)Cohort 2: SC (Vial) Herceptin (Continuation)Cohort 2 Overall: SC (Vial) and IV Herceptin
AstheniaGeneral disorders13/24210/2419/2260/4330/24417/23715/2370/1011/20836/239
ArthralgiaMusculoskeletal and connective tissue disorders10/24215/24112/2261/4333/24415/23712/2370/1010/20833/239
HeadacheNervous system disorders8/2426/24110/2260/4321/24412/23711/2370/1011/20829/239
Hot flushVascular disorders8/2426/2413/2261/4318/24414/23711/2370/105/20827/239
Injection site painGeneral disorders12/2420/2410/2262/4313/24420/2370/2370/106/20824/239
FatigueGeneral disorders8/24210/2417/2260/4323/24411/2378/2371/105/20821/239
NasopharyngitisInfections and infestations5/2427/2415/2261/4316/2446/2373/2371/106/20813/239
Chest painGeneral disorders0/2420/2410/2260/430/2443/2372/2371/100/2086/239
Medical device discomfortGeneral disorders0/2420/2410/2260/430/2440/2370/2371/100/2081/239
MyalgiaMusculoskeletal and connective tissue disorders0/2420/2410/2260/430/2442/2373/2371/104/20810/239

Baseline characteristics

Safety Population: All participants who received at least one dose of Herceptin.

Age, Continuous
Age, Continuous(years)Cohort 1 Overall: SC (SID) and IV HerceptinCohort 2 Overall: SC (Vial) and IV HerceptinTotal
Mean53.3 ± 11.4052.9 ± 10.8753.1 ± 11.13
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1 Overall: SC (SID) and IV HerceptinCohort 2 Overall: SC (Vial) and IV HerceptinTotal
Female244239483
Male000
08

Study locations

75 sites
  • Barrie, Ontario L4M 6M2, Canada
  • Brampton, Ontario L6R 3J7, Canada
  • Kitchener, Ontario N2G 1G3, Canada
  • Sault Ste Marie, Ontario P6A 2C4, Canada
  • Toronto, Ontario M4N 3M5, Canada
  • Saskatoon, Saskatchewan S7N 4H4, Canada
  • Herning, 7400, Denmark
  • Odense, 5000, Denmark
  • Vejle, 7100, Denmark
  • Besancon, 25030, France
  • Bobigny, 93009, France
  • Bordeaux, 33076, France
  • Caen, 14076, France
  • La Tronche, 38700, France
  • LeMans, 72000, France
  • Lyon, 69373, France
  • Paris, 75970, France
  • Rennes, 35042, France
  • St Cloud, 92210, France
  • Strasbourg, 67065, France
  • Berlin, 10713, Germany
  • Deggendorf, 94469, Germany
  • Essen, 45136, Germany
  • Fuerstenwalde, 15517, Germany
  • Hamburg, 20246, Germany
  • Hannover, 30625, Germany
  • Magedburg, 39104, Germany
  • Mainz, 55131, Germany
  • Meiningen, 98617, Germany
  • Recklinghausen, 45657, Germany
  • Ulm, 89073, Germany
  • Genova, Liguria 16132, Italy
  • Milano, Lombardia 20132, Italy
  • Milano, Lombardia 20141, Italy
  • Pavia, Lombardia 27100, Italy
  • Antella (FI), Toscana 50011, Italy
  • Terni, Umbria 05100, Italy
  • Gdansk, 80-952, Poland
  • Warszawa, 02-781, Poland
  • Ekaterinburg, 620905, Russian Federation
  • Irkutsk, 664035, Russian Federation
  • Kazan, 420029, Russian Federation
  • Moscow, 115478, Russian Federation
  • Orenburg, 460021, Russian Federation
  • Saint-Petersburg, 197758, Russian Federation
  • St Petersburg, Russian Federation
  • Oviedo, Asturias 33006, Spain
  • Barakaldo, Vizcaya 48903, Spain
  • Barcelona, 08024, Spain
  • Cordoba, 14004, Spain
  • Guadalajara, 19002, Spain
  • Huesca, 22004, Spain
  • Madrid, 28046, Spain
  • Madrid, 28905, Spain
  • Malaga, 29010, Spain
  • Sevilla, 41009, Spain
  • Sevilla, 41014, Spain
  • Zamora, 49021, Spain
  • Eskilstuna, 63188, Sweden
  • Gävle, 80187, Sweden
  • Jonkoping, 55185, Sweden
  • Sundsvall, 85186, Sweden
  • Baden, 5405, Switzerland
  • Zürich, 8008, Switzerland
  • Adana, 01120, Turkey
  • Ankara, 06018, Turkey
  • Bornova, ?ZM?R, 35100, Turkey
  • Gaziantep, 27310, Turkey
  • Brighton, BN2 5BE, United Kingdom
  • Cardiff, CF14 2TL, United Kingdom
  • Chelmsford, CM1 7ET, United Kingdom
  • Maidstone, ME16 9QQ, United Kingdom
  • Nottingham, NG5 1PB, United Kingdom
  • Peterborough, PE3 6DA, United Kingdom
  • Truro, TR1 3LJ, United Kingdom
09

References and documents

Publications

  • Pivot X, Verma S, Fallowfield L, Muller V, Lichinitser M, Jenkins V, Sanchez Munoz A, Machackova Z, Osborne S, Gligorov J; PrefHer Study Group. Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study. Eur J Cancer. 2017 Nov;86:82-90. doi: 10.1016/j.ejca.2017.08.019. Epub 2017 Sep 28. PubMed 28963915 ↗
  • Gligorov J, Curigliano G, Muller V, Knoop A, Jenkins V, Verma S, Osborne S, Lauer S, Machackova Z, Fallowfield L, Pivot X. Switching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial. Breast. 2017 Aug;34:89-95. doi: 10.1016/j.breast.2017.05.004. Epub 2017 May 23. PubMed 28549309 ↗
  • De Cock E, Pivot X, Hauser N, Verma S, Kritikou P, Millar D, Knoop A. A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer. Cancer Med. 2016 Mar;5(3):389-97. doi: 10.1002/cam4.573. Epub 2016 Jan 25. PubMed 26806010 ↗
  • Pivot X, Gligorov J, Muller V, Curigliano G, Knoop A, Verma S, Jenkins V, Scotto N, Osborne S, Fallowfield L; PrefHer Study Group. Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. Ann Oncol. 2014 Oct;25(10):1979-1987. doi: 10.1093/annonc/mdu364. Epub 2014 Jul 28. PubMed 25070545 ↗
  • Pivot X, Gligorov J, Muller V, Barrett-Lee P, Verma S, Knoop A, Curigliano G, Semiglazov V, Lopez-Vivanco G, Jenkins V, Scotto N, Osborne S, Fallowfield L; PrefHer Study Group. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol. 2013 Sep;14(10):962-70. doi: 10.1016/S1470-2045(13)70383-8. Epub 2013 Aug 19. PubMed 23965225 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2011, a primary completion of May 2013 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2015, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2011
First posted
Jul 25, 2011
Start
Oct 2011
Primary completionActual
May 2013
CompletionActual
Dec 2015
Results first posted
Jun 8, 2015
Last update
Mar 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01401166
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jul 25, 2011
Start date
Oct 2011
Primary completion
May 2013
Completion
Dec 2015
Results posted
Jun 8, 2015
Last update
Mar 6, 2017

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab

Start the discussion